<DOC>
	<DOCNO>NCT02619630</DOCNO>
	<brief_summary>The purpose study evaluate efficacy nelarabine-based consolidation maintenance therapy term relapse-free survival ( RFS ) high-risk ( HR ) patient .</brief_summary>
	<brief_title>Multicenter Study Risk-adapted Treatment T-lineage ALL Young Adults ( 18-59 Years Old )</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>1 . Whose blood bone marrow exploration complete steroid prephase 2. aged 1859 year old previously treat ( include IT injection ) TALL newlydiagnosed accord WHO 2008 definition &gt; 20 % bone marrow blast 3 . With Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 3 4 . With without central nervous system ( CNS ) involvement testis 5 . Without evolve cancer ( except basal cell carcinoma skin `` situ '' carcinoma cervix ) chemo radiotherapy treatment finish least since 6 month 6 . Having sign write informed consent 7 . With efficient contraception woman childbearing age ( exclude estrogen IUD ) 8 . Having receive receive steroid prephase 9 . With health insurance coverage 1 . With lymphoblastic lymphoma bone marrow blast &lt; 20 % , Burkitttype ALL antecedents chronic myeloid leukemia ( CML ) myeloproliferative neoplasm 2 . With contraindication anthracyclines general visceral contraindication intensive therapy except consider related ALL : Aspartate transaminase ( AST ) and/or alanine transaminase ( ALT ) &gt; 5 x upper limit normal range ( ULN ) Total bilirubin â‰¥ 2.5 x upper limit normal range ( ULN ) Creatinine &gt; 1.5 x upper limit normal range ( ULN ) creatinine clearance &lt; 50 mL/mn 3 . Myocardial infarction within 6 month prior inclusion trial , cardiomyopathy ( NYHA grade III IV ) , leave ejection ventricle fraction ( LEVF ) &lt; 50 % and/or RF &lt; 30 % , 4 . Active severe infection know seropositivity HIV Human T cell leukemia/lymphoma virus type 1 ( HTLV1 ) active hepatitis B C 5 . Other active malignancy 6 . Pregnant ( betaHuman Chorionic Gonadotropin ( hCG ) positive ) nurse woman 7 . Women childbearing potential willing use effective form contraception participation study least three month thereafter . Patients willing ensure beget child participation study least three month thereafter 8 . Treated investigational agent participation another trial within 30 day prior enter study 9 . Not able bear procedure frequency visit plan trial 10 . Unable consent , tutelage curator , judiciary safeguard</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>